Back
Also listed as
HKMPF
OTC
Day Range
$34.00
$34.17
52-Week Range
$31.80
$56.94
Volume
300
50D / 200D Avg
$39.84
/
$45.96
Prev Close
$33.05
Quick Summary
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (631 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 9.3 | 0.2 |
| P/B | 1.4 | 3.0 |
| ROE % | 16.4 | 3.6 |
| Net Margin % | 12.0 | 3.8 |
| Rev Growth 5Y % | 7.1 | 9.9 |
| D/E | 0.6 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2027 |
$0.00
$0.00 – $0.00
|
3.64B | 0 |
| FY2026 |
$0.00
$0.00 – $0.00
|
3.47B | 0 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-24 | N/A | $1.46 | — |
| 2025-08-07 | N/A | $2.14 | — |
| 2025-02-26 | N/A | $0.59 | — |
| 2024-08-08 | N/A | $1.01 | — |
| 2024-04-25 | N/A | $0.52 | — |
| 2023-06-30 | N/A | $1.18 | — |
| 2022-12-31 | N/A | $0.14 | — |
| 2022-06-30 | N/A | $1.52 | — |
Dividend History
7 yr streakYield
0.04%
Payout Ratio
0.46%
Growth (3Y)
15.16%
Growth (5Y)
13.30%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Mar 20, 2026 | May 11, 2026 | $0.94 | 4.86% |
| Aug 18, 2025 | Sep 29, 2025 | $0.72 | 3.41% |
| Mar 21, 2025 | May 12, 2025 | $0.96 | 2.95% |
| Aug 19, 2024 | Sep 30, 2024 | $0.64 | 2.84% |
| Mar 21, 2024 | May 13, 2024 | $0.94 | 2.92% |
| Aug 11, 2023 | Sep 25, 2023 | $0.48 | 2.17% |
| Mar 23, 2023 | May 15, 2023 | $0.74 | 2.71% |
| Aug 18, 2022 | Sep 30, 2022 | $0.38 | 3.18% |
| Mar 17, 2022 | May 09, 2022 | $0.72 | 1.91% |
| Aug 25, 2021 | Sep 30, 2021 | $0.36 | 1.43% |
| Mar 18, 2021 | May 06, 2021 | $0.68 | 1.68% |
| Aug 20, 2020 | Oct 01, 2020 | $0.32 | 1.47% |
| Mar 19, 2020 | May 18, 2020 | $0.58 | 1.72% |
| Aug 22, 2019 | Oct 03, 2019 | $0.28 | 1.64% |
| Apr 04, 2019 | Jun 03, 2019 | $0.52 | 1.56% |
| Aug 24, 2018 | Oct 12, 2018 | $0.24 | 1.74% |
| Apr 05, 2018 | Jun 04, 2018 | $0.46 | 1.99% |
| Aug 30, 2017 | Oct 02, 2017 | $0.22 | 2.12% |
| Apr 05, 2017 | Jun 05, 2017 | $0.44 | 1.25% |
| Sep 01, 2016 | — | $0.22 | 0.96% |
Key Takeaways
Revenue grew 7.08% annually over 5 years — modest growth
ROE of 16.44% — decent returns on equity
Generating 162.38M in free cash flow
P/E of 9.29 — trading at a low valuation
PEG of 0.89 suggests growth is underpriced
Capital efficient — spends only 5.88% of revenue on capex
Growth
Revenue Growth (5Y)
7.08%
Revenue (1Y)7.35%
Earnings (1Y)12.24%
FCF Growth (3Y)-36.60%
Quality
Return on Equity
16.44%
ROIC11.06%
Net Margin12.00%
Op. Margin18.63%
Safety
Debt / Equity
0.64
Current Ratio1.82
Interest Coverage5.89
Valuation
P/E Ratio
9.29
Forward P/EN/A
P/B Ratio1.44
EV/EBITDA8.09
Dividend Yield0.04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7.35% | Revenue Growth (3Y) | 8.06% |
| Earnings Growth (1Y) | 12.24% | Earnings Growth (3Y) | 45.63% |
| Revenue Growth (5Y) | 7.08% | Earnings Growth (5Y) | -1.09% |
| Profitability | |||
| Revenue (TTM) | 3.36B | Net Income (TTM) | 402.94M |
| ROE | 16.44% | ROA | 7.11% |
| Gross Margin | 40.04% | Operating Margin | 18.63% |
| Net Margin | 12.00% | Free Cash Flow (TTM) | 162.38M |
| ROIC | 11.06% | FCF Growth (3Y) | -36.60% |
| Safety | |||
| Debt / Equity | 0.64 | Current Ratio | 1.82 |
| Interest Coverage | 5.89 | ||
| Dividends | |||
| Dividend Yield | 0.04% | Payout Ratio | 0.46% |
| Dividend Growth (3Y) | 15.16% | Dividend Growth (5Y) | 13.30% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 9.29 | Forward P/E | N/A |
| P/B Ratio | 1.44 | P/S Ratio | 1.11 |
| PEG Ratio | 0.89 | Forward PEG | N/A |
| EV/EBITDA | 8.09 | Fwd EV/EBITDA | 5.84 |
| Forward P/S | 1.08 | Fwd Earnings Yield | N/A |
| FCF Yield | 4.34% | ||
| Market Cap | 3.74B | Enterprise Value | 5.06B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.36B | 3.13B | 2.88B | 2.52B | 2.55B |
| Net Income | 402.94M | 359.00M | 190.00M | 188.00M | 421.00M |
| EPS (Diluted) | 3.62 | 3.22 | 1.72 | 1.68 | 3.62 |
| Gross Profit | 1.34B | 1.42B | 1.41B | 1.24B | 1.30B |
| Operating Income | 625.46M | 612.00M | 367.00M | 282.00M | 582.00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 5.67B | 5.13B | 4.68B | 4.47B | 4.37B |
| Total Liabilities | 3.07B | 2.81B | 2.47B | 2.32B | 1.91B |
| Shareholders' Equity | 2.59B | 2.31B | 2.20B | 2.14B | 2.45B |
| Total Debt | 1.65B | 1.31B | 1.19B | 1.28B | 846.00M |
| Cash & Equivalents | 328.00M | 188.00M | 205.00M | 270.00M | 426.00M |
| Current Assets | 2.64B | 2.26B | 2.10B | 2.00B | 2.09B |
| Current Liabilities | 1.45B | 1.98B | 1.34B | 1.08B | 1.02B |
Strategy Scores
This stock passed the criteria for 0 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recent Activity
Exited
Contrarian Investing (David Dreman)
Mar 26, 2026
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026